Bessemer Group
NTLA icon

Bessemer Group’s Intellia Therapeutics NTLA Stock Holding History

Bessemer Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-189
Closed -$14K – 1985
2022
Q1 		$14K Buy
+189
New +$16K ﹤0.01% 1322

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bessemer Group's NTLA Position: Q2 2022 in Review

Bessemer Group sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 189 shares — an estimated $14K sold.

Bessemer Group first reported a position in NTLA in Q1 2022 and held it in 1 quarter. The position peaked at $14K in Q1 2022. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Bessemer Group reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bessemer Group sold 189 Intellia Therapeutics shares in Q2 2022, an estimated $14K.
  • Bessemer Group first reported a position in Intellia Therapeutics in Q1 2022 and held it in 1 quarter.
  • Bessemer Group's Intellia Therapeutics position peaked at $14K in Q1 2022.
  • 299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Bessemer Group's 13F filing for Q2 2022, filed 10 Aug 2022.